Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

However, for people like Anna Engomba, the arrival of new, life-saving medication ... of the limited available treatment options. While the numbers of people with HIV remains high, treatment ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Among recipients with HIV, kidney transplantation from donors with HIV is noninferior to that from donors without HIV.